Shares of Krystal Biotech, Inc. (KRYS) , a commercial-stage biotechnology company, have surged 21.9% year to date compared with the industry's growth of 7.8%. The stock has also outperformed the Medical sector and S&P 500 Index during the same timeframe. The rally can be mostly attributed to the strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress. Earlier this month, the company reported better-than-expected second-quarter results, wherein both earnings and sales beat their re ...